Zentiva N.V., a prominent player in the pharmaceutical industry, is headquartered in the Netherlands (NL) and operates extensively across Europe. Founded in 1998, the company has established itself as a leader in the generic and specialty medicines sector, focusing on high-quality, affordable healthcare solutions. Zentiva's core offerings include a diverse range of generic pharmaceuticals, over-the-counter products, and specialty medicines, all designed to meet the evolving needs of patients and healthcare providers. The company is recognised for its commitment to quality and innovation, ensuring that its products are both effective and accessible. With a strong market position, Zentiva has achieved significant milestones, including expanding its product portfolio and enhancing its manufacturing capabilities. This dedication to excellence has solidified Zentiva's reputation as a trusted partner in the healthcare landscape.
How does Zentiva N.V.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Zentiva N.V.'s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Zentiva N.V., headquartered in the Netherlands, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Sanofi, and as such, it inherits emissions data and climate commitments from its parent organisation. Zentiva's climate initiatives are aligned with those of Sanofi, which has set ambitious targets to reduce its carbon footprint. However, specific reduction targets or achievements for Zentiva itself have not been disclosed. The company is part of various sustainability initiatives, including the Science Based Targets initiative (SBTi), CDP, and RE100, all of which are cascaded from Sanofi. As a subsidiary, Zentiva is expected to contribute to the overarching climate goals set by Sanofi, which include significant reductions in greenhouse gas emissions across all scopes. The lack of specific emissions data and reduction targets for Zentiva highlights the need for further transparency in its climate commitments.
Access structured emissions data, company-specific emission factors, and source documents
2010 | 2011 | 2012 | 2013 | 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 545,114,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 677,549,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | - | 0,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zentiva N.V. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.